Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis
Peritoneal Neoplasms|Intestinal Obstruction|Carcinomatosis
DRUG: Octreotide LAR|DRUG: Octreotide (Immediate release)|DRUG: methylprednisolone|DRUG: Placebo
Number of Participants With Treatment Success From Day 10 to Day 13, Treatment Success was defined as: less than 2 episodes of vomiting on average per day for the 4 days prior to Day 14 \[from Day 10 to Day 13\] and no use of an Nasogastric Tube (NGT) since at least Day 10 and no use of an anticholinergic agent until Day 14.

Treatment Failure is defined as: 2 or more episodes of vomiting per day on average for the 4 days prior to Day 14 or use of an NGT after Day 9 or use of an anticholinergic agent before Day 14 or withdrawal from the trial between Day 1 and Day 14 (included), whatever the cause., Day 10 to Day 13
Number of Participants With Treatment Success From Day 5 to Day 7, Day 7 treatment success was defined as improvement of symptoms in the previous 2 days (average number of vomiting episodes less than 2 from Day 5, no Nasogastric Tube (NGT) since Day 5 and no anticholinergic agent or withdrawal from trial)., Day 5 to Day 7|Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14, The mean number of vomiting episodes per a 24 hour period is presented for Day 1, Day 7 and Day 14., Day 1, Day 7 and Day 14|Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1, Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 1., Day 1|Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7, Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 7., Day 7|Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14, Participants rated their nausea intensity on a scale of 0 to 3, with 3 being the worse. The number of participants with a score of 0, a score of 1, a score of 2 and a score of 3 are presented for Day 14., Day 14|Number of Participants With Relief From Obstruction at Day 7 and Day 14, Relief from obstruction is defined by combining restart of stools for at least the previous 3 days, less than 2 episodes of vomiting on average for the previous 4 days and the restarting of flatus (gas generated in the stomach or bowels) for at least the previous 12 hours., Day 7 and Day 14|Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1, Recurrence of bowel obstruction was confirmed by abdominal X-ray., 1 Month|Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2, Recurrence of bowel obstruction was confirmed by abdominal X-ray., Month 2|Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3, Recurrence of bowel obstruction was confirmed by abdominal X-ray., Month 3|Participant's Quality of Life Using the Edmonton Scale, The Edmonton Scale consisted of 9 items: pain, activity, nausea, depression, anxiety, fatigue, appetite, sensation of well-being and dyspnea (difficult or labored breathing). Participants rated these items on a scale of 0 to 10, with 10 being the worse., Day 1, Day 7, Day 14, Month 1, Month 2 and Month 3
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis